Matej Hrunka

Matej Hrunka

Auto-generated profile, based on publicly available information

Matej Hrunka

Department of Pediatrics, University Hospital Brno, Faculty of Medicine Masaryk University Brno Czech Republic

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 December 2023 in Journal of Gastrointestinal and Liver Diseases
Verified
Journal Article
Open access
PDF file
MHMatěj Hrunka
Matěj Hrunka
LJLubomir Janda
Lubomir Janda
MŠMichaela Šťastná
Michaela Šťastná
TPTereza Pinkasová
Tereza Pinkasová
JPJakub Pecl
Jakub Pecl
PJPetr Jabandziev
Petr Jabandziev
Celiac disease is a common gastroenterological illness. Current diagnostics of the disease are based on serological markers and histology of duodenal biopsies. Hitherto, a strict gluten-free diet is the only effective treatment and is necessary for good control of the disease. Serological tests in current use have very high specificity and sensitivity for diagnostics, but in follow-up they have some limitations. Their levels do not accurately reflect mucosal healing, and they are unable to detect minimal transgressions in the diet. This problem is significant in patients with IgA deficiency, and there exist no robust follow-up tools for monitoring these patients’ adherence to treatment. For their follow-up, we currently use IgG-based tests, and these antibodies persist for a long time even when a patient has stopped consuming gluten. More accurate and specific biomarkers are definitely needed. Adherence to a gluten-free diet is essential not only for intestinal mucosa healing and alleviation of symptoms but also for preventing complications associated with celiac disease. Here, we summarize current evidence regarding noninvasive biomarkers potentially useful for follow-up not only of patients with IgA deficiency but for all patients with celiac disease. We describe several very promising biomarkers with potential to be part of clinical practice in the near future.

11 December 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
LKLumir Kunovsky
Lumir Kunovsky
PDPetr Dite
Petr Dite
PJPetr Jabandziev
Petr Jabandziev
ZKZdenek Kala
Zdenek Kala
JVJitka Vaculova
Jitka Vaculova
JTJan Trna
Jan Trna
It is well known that some pathological conditions, especially of autoimmune etiology, are associated with the HLA (human leukocyte antigen) phenotype. Among these diseases, we include celiac disease, inflammatory bowel disease, autoimmune enteropathy, autoimmune hepatitis, primary sclerosing cholangitis and primary biliary cholangitis. Immunoglobulin G4-related diseases (IgG4-related diseases) constitute a second group of autoimmune gastrointestinal, hepatobiliary and pancreatic illnesses. IgG4-related diseases are systemic and rare autoimmune illnesses. They often are connected with chronic inflammation and fibrotic reaction that can occur in any organ of the body. The most typical feature of these diseases is a mononuclear infiltrate with IgG4-positive plasma cells and self-sustaining inflammatory response. In this review, we focus especially upon the hepatopancreatobiliary system, autoimmune pancreatitis and IgG4-related sclerosing cholangitis. The cooperation of the gastroenterologist, radiologist, surgeon and histopathologist is crucial for establishing correct diagnoses and appropriate treatment, especially in IgG4 hepatopancreatobiliary diseases.

26 August 2025 in Inflammatory Bowel Diseases
Verified
Journal Article
Open access
TDTereza Deissova
Tereza Deissova
DTDagmar Al Tukmachi
Dagmar Al Tukmachi
LRLenka Radova
Lenka Radova
JBJúlia Bohošová
Júlia Bohošová
TMTana Machackova
Tana Machackova
PJPetr Jabandziev
Petr Jabandziev
Background: Identifying novel diagnostic and prognostic biomarkers for pediatric inflammatory bowel diseases (PIBD), including Crohn’s disease (pCD) and ulcerative colitis (pUC), is essential for enhancing treatment outcomes. MicroRNAs (miRNAs) have been recognized for their broader relevance in PIBD pathogenesis. This study investigates their diagnostic potential and clinical utility in PIBD. Methods: This prospective, monocentric study, with retrospective validation, involved 119 PIBD patients (58 pCD, 61 pUC) and 39 non-IBD controls. Small RNA next-generation sequencing was performed on fresh-frozen gut biopsies, targeting histopathologically confirmed inflamed areas. Twenty-five dysregulated miRNA candidates were validated via RT-qPCR in formalin-fixed, paraffin-embedded gut biopsies. Logistic regression was used to establish diagnostic and prognostic miRNA expression signatures. Results: A diagnostic signature of 5 miRNAs (miR-223-3p, miR-34a-5p, miR-194-5p, miR-215-5p, miR-338-3p) distinguished pCD from non-IBD with 96.49% accuracy. Two miRNAs (miR-223-3p, miR-194-5p) differentiated pUC from non-IBD with 100% accuracy, and miR-215-5p distinguished pCD from pUC specimens with 83.54% accuracy. For treatment-naïve pCD patients, 7 miRNAs predicted residual disease activity at 3 months with 100% accuracy. Additionally, a distinct signature predicted the risk of relapse within 12 months with an accuracy of 84.21%. Conclusions: In this study, we have established tissue miRNA expression signatures with significant diagnostic and prognostic potential for use in PIBD. These findings aid in stratifying disease severity and risk, paving the way for more precise and personalized management of pediatric IBD.

1 May 2025 in BMC Pediatrics
Verified
Journal Article
Open access
PDF file
MAMartina Ambrozová
Martina Ambrozová
MHMatěj Hrunka
Matěj Hrunka
MJMarta Ježová
Marta Ježová
Milan UríkMilan Urík
Milan Urík
PJPetr Jabandziev
Petr Jabandziev
There exist multiple extraintestinal manifestations of inflammatory bowel disease. The most common are arthritis, aphthous stomatitis, or uveitis. Aseptic abscess syndrome is not usually included among these extraintestinal manifestations. In our case report, we present a rare case of aseptic abscess syndrome as the first manifestation of inflammatory bowel disease. We present the case of a 10-year-old girl whose only initial medical issue was recurrent submandibular lymphadenitis unresponsive to standard antibiotic therapy. A broad differential diagnosis was initiated to exclude an infectious etiology. Eventually, it was necessary to proceed with extirpation of the suspected lymph node. Histological examination showed suppurative granulomatous inflammation, so it was further examined for noninfectious cause. Blood tests revealed positivity of ASCA antibodies (Anti-Saccharomyces cerevisiae) in both IgA and IgG classes. Despite absence of typical gastrointestinal symptoms, bowel ultrasound was performed, followed by magnetic resonance enterography. Both showed inflammatory changes in the terminal ileum. Subsequent endoscopy of the gastrointestinal tract and histological examination of biopsy specimens confirmed a diagnosis of Crohn’s disease with terminal ileum and rectum involvement. A standard treatment based on current guidelines led to remission without recurrence of lymphadenitis. In cases of lymphadenitis that does not respond to standard antibiotic treatment, diagnosis of aseptic abscess syndrome should be considered as a potential etiology and, subsequently, inflammatory bowel disease should be investigated, given that this syndrome is associated with inflammatory bowel disease in as many as 70% of cases. To our knowledge, this is the first published case report describing aseptic abscess syndrome affecting cervical lymph nodes as an extraintestinal manifestation of pediatric Crohn’s disease.

15 October 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
MŠMichaela Šťastná
Michaela Šťastná
ANAdam Norek
Adam Norek
PMPeter Makovický
Peter Makovický
EJEdita Jeklová
Edita Jeklová
PSPetra Straková
Petra Straková
LJLubomir Janda
Lubomir Janda
Dietary cereal prolamins differ in composition and gastrointestinal processing, but their shared and protein-source-specific effects on intestinal homeostasis remain incompletely defined. BALB/c mice were fed for five weeks with diets in which 70% of total protein was supplied by vital wheat gluten, purified gliadin, or purified avenin, alongside casein-fed controls. Intestinal morphology, antigen-specific plasma immunoglobulin G and A (IgG, IgA), mucosal gene expression, and small-intestinal proteomics were analysed. No overt histopathological injury or generalised inflammatory response was detected in any group. Gliadin and avenin both increased ileal villus length; avenin additionally elicited the broadest and most frequent prolamin-specific IgG response, associated with reduced intestinal interleukin-10 expression in responding animals. Proteomic profiling revealed a shared structural-metabolic signature alongside protein-specific changes in lipid handling, junctional regulation, and epithelial immune signalling. These findings indicate that wheat-and oat-derived prolamins differentially influence intestinal homeostasis and antigen recognition even at matched dietary doses, informing their evaluation as functional food ingredients. Graphical

26 October 2026 in Journal of Pediatric Gastroenterology and Nutrition
Verified
Journal Article
Open access
TPTereza Pinkasova
Tereza Pinkasova
TDTereza Deissova
Tereza Deissova
MHMatej Hrunka
Matej Hrunka
MAMartina Ambrozova
Martina Ambrozova
DTDagmar Al Tukmachi
Dagmar Al Tukmachi
PJPetr Jabandziev
Petr Jabandziev
Objectives: The identification of novel noninvasive diagnostic and prognostic biomarkers for pediatric inflammatory bowel disease (PIBD), including pediatric Crohn's disease (pCD) and ulcerative colitis (pUC), is crucial for improving therapeutic outcomes. Given their involvement in PIBD pathogenesis, microRNAs (miRNAs) represent promising candidates. This study investigates their potential diagnostic value and clinical utility. Methods: The study involved 81 treatment‐naive PIBD patients and 30 non‐IBD controls from whom stool samples were collected. Fecal microRNA analysis was performed using small RNA next‐generation sequencing. Differentially expressed miRNAs (DEMs) were identified in the exploratory phase (34 PIBD, 20 non‐IBD children). Logistic regression was used to establish diagnostic and prognostic miRNA expression signatures. The designed miRNA panels were validated using leave‐one‐out cross‐validation and on an independent cohort (47 PIBD, 10 non‐IBD children). Results: A diagnostic signature of four fecal miRNAs (10392‐5p, miR‐1246, miR‐4695‐5p, and miR‐5006‐5p) distinguished pCD from non‐IBD with 79.55% accuracy. Three fecal miRNAs (miR‐1290, miR‐3960, and miR‐5006‐5p) differentiated pUC from non‐IBD with 78.26% accuracy. For treatment‐naïve PIBD patients, panels of five and six miRNAs predicted residual disease activity at 3 months with 100% accuracy for pUC patients and 86.28% accuracy for pCD patients. Additionally, distinct signatures of four and six miRNAs predicted relapse within 12 months with accuracies of 96.87% (pUC) and 88.01% (pCD), respectively. Conclusion: We identified fecal miRNA expression profiles with strong diagnostic and prognostic value in PIBD. These results contribute to improved stratification of disease severity and risk, supporting the advancement of precision and personalized approaches in pediatric IBD management.